Table 2.
Mean annual percent change (APC) and 95% CI by sex in crude rate of incidence (A) and mortality (B) by site and time
| (A)
|
(B)
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APC, incidence in men (lower CI–upper CI)
|
APC, incidence in women (lower CI–upper CI)
|
APC, mortality in men (lower CI–upper CI)
|
APC, mortality in women (lower CI–upper CI)
|
||||||||||
| Site | 2001–2014 | 2015–2030 | Site | 2001–2014 | 2015–2030 | Site | 1996–2005 | 2006–2015 | 2016–2030 | Site | 1996–2005 | 2006–2015 | 2016–2030 |
| Lung and bronchus | −0.7* (−0.9 to −0.5) | −0.7* (−0.9 to −0.5) | Breast | 1.5 (−0.6 to 3.7) | 1.9* (1.6 to 2.2) | Pancreas | 0.3 (−1.0 to 1.6) | 1.9* (1.7 to 2.1) | 1.9* (1.7 to 2.1) | Pancreas | 2.1* (2.0 to 2.3) | 2.1* (2.0 to 2.3) | 2.1* (2.0 to 2.3) |
| Colorectal | 2.1* (1.9 to 2.3) | 2.1* (1.9 to 2.3) | Colorectal | 1.3* (1.1 to 1.5) | 1.3* (1.1 to 1.5) | Oral cavity and pharynx | 1.0* (0.2 to 1.8) | −1.8* (−2.0 to −1.6) | −1.8* (−2.0 to −1.6) | Oral cavity and pharynx | 3.4* (0.1 to 6.8) | 1.2* (0.8 to 1.6) | 1.2* (0.8 to 1.6) |
| Prostate | 3.6* (3.1 to 4.1) | 3.6* (3.1 to 4.1) | Lung and bronchus | 1.7* (1.4 to 1.9) | 1.7* (1.4 to 1.9) | Lung and bronchus | −0.1 (−0.2 to 0.0) | −0.1 (−0.2 to 0.0) | −0.1 (−0.2 to 0.0) | Lung and bronchus | 2.4* (1.7 to 3.1) | 3.9* (2.9 to 5.0) | 2.1* (1.8 to 2.4) |
| Oral cavity and pharynx | −0.7* (−1.0 to −0.4) | −0.7* (−1.0 to −0.4) | Corpus uteri | 2.1* (1.7 to 2.4) | 2.1* (1.7 to 2.4) | Colorectal | 1.0* (0.7 to 1.2) | 1.0* (0.7 to 1.2) | 2.5* (1.6 to 3.4) | Colorectal | 2.4* (1.7 to 3.1) | 3.9* (2.9 to 5.0) | 2.1* (1.8 to 2.4) |
| Bladder | 2.5* (2.2 to 2.9) | 2.5* (2.2 to 2.9) | Cervix uteri | −0.8 (−2.8 to 1.2) | 0.5 (−0.9 to 1.9) | Stomach | −2.3* (−2.7 to −1.9) | −2.3* (−2.7 to −1.9) | 1 (−0.6 to 2.5) | Stomach | −3.1* (−4.0 to −2.1) | −0.2 (−0.6 to 0.2) | 0.2 (−0.3 to 0.7) |
| Stomach | −0.2 (−0.6 to 0.1) | −0.2 (−0.6 to 0.1) | Ovary | 1.4 (−0.3 to 3.2) | 0.8* (0.3 to 1.3) | Gallbladder and biliary tract | −1.6* (−2.3 to −0.9) | 0 (−0.5 to 0.5) | 2.0* (1.3 to 2.7) | Gallbladder and biliary tract | −3.8* (−4.5 to −3.1) | −1.7* (−2.2 to −1.2) | 0 (−0.7 to 0.7) |
| Kidney | 2.4* (2.0 to 2.7) | 2.4* (2.0 to 2.7) | Stomach | 0.1 (−0.2 to 0.4) | 0.1 (−0.2 to 0.4) | Leukemia | −0.6 (−1.3 to 0.0) | 0.3 (−0.1 to 0.7) | 1.5* (0.9 to 2.2) | Leukemia | 0 (−0.5 to 0.5) | 0.1 (−0.3 to 0.6) | 1.4* (0.3 to 2.4) |
| Pancreas | 2.6* (2.2 to 2.9) | 2.6* (2.2 to 2.9) | Pancreas | 4.3* (3.2 to 5.4) | 3.0* (2.5 to 3.4) | Liver | −0.1 (−1.6 to 1.3) | 2.5* (0.7 to 4.2) | 1.0* (0.3 to 1.6) | Liver | −3.2* (−4.3 to −2.0) | −0.1 (−0.7 to 0.6) | 2.5* (1.5 to 3.4) |
| Larynx | −1.2* (−1.7 to −0.8) | −1.2* (−1.7 to −0.8) | Oral cavity and pharynx | 2.7* (0.1 to 5.4) | 1.5* (0.9 to 2.1) | Bladder | −0.2 (−1.3 to 0.9) | 2.3* (1.9 to 2.7) | 2.6* (2.1 to 3.0) | Bladder | 2.3* (2.0 to 2.6) | 2.3* (2.0 to 2.6) | 2.3* (2.0 to 2.6) |
| Brain | 0.8* (0.5 to 1.1) | 0.8* (0.5 to 1.1) | Brain | 0.7* (0.3 to 1.2) | 0.7* (0.3 to 1.2) | Larynx | −1.2* (−1.4 to −0.9) | −1.2* (−1.4 to −0.9) | −1.2* (−1.4 to −0.9) | Breast | −0.9 (−2.3 to 0.5) | 1.1* (0.9 to 1.3) | 1.1* (0.9 to 1.3) |
| Leukemia | 2.3* (1.9 to 2.7) | 2.3* (1.9 to 2.7) | Melanoma of skin | 4.6* (1.5 to 7.9) | 2.6* (2.2 to 2.3) | Esophagus | −1.5* (−1.8 to −1.2) | −1.5* (−1.8 to −1.2) | −1.5* (−1.8 to −1.2) | Ovary | 1.4* (1.2 to 1.5) | 1.4* (1.2 to 1.5) | 1.4* (1.2 to 1.5) |
| Melanoma of skin | 6.0* (4.2 to 7.9) | 3.1* (2.3 to 3.9) | Bladder | 2.9* (2.5 to 3.3) | 2.9* (2.5 to 3.3) | Bones and joints | −8.0* (−12.8 to −2.9) | −5.0* (−9.6 to −0.3) | −2.4* (−4.4 to −0.2) | Cervix uteri | −2.1* (−2.9 to 1.3) | 0.2 (−0.3 to 1.7) | 1.4* (0.8 to 2.0) |
| Liver | 4.1* (2.7 to 5.4) | 1.9* (1.3 to 2.6) | Leukemia | 1.6* (1.2 to 2.0) | 1.6* (1.2 to 2.0) | Kidney | −0.6 (−1.5 to 0.3) | 1.4* (1.1 to 1.8) | 1.7* (1.3 to 2.1) | Corpus uteri | −3.8 (−8.3 to 0.8) | 3.7* (1.2 to 6.2) | −0.4 (−1.7 to 1.0) |
| Non-Hodgkin lymphoma | 2.6* (2.2 to 3.0) | 2.6* (2.2 to 3.0) | Kidney | 2.3* (2.0 to 2.6) | 2.3* (2.0 to 2.6) | Prostate | −1.3* (−1.8 to −0.8) | 0.6* (0.3 to 0.9) | 3.0* (2.6 to 3.5) | Brain | −2.0* (−3.2 to 0.9) | 0.4 (−0.3 – 1.0) | 1.6* (0.8 to 2.4) |
| Esophagus | −0.8* (−1.2 to −0.4) | −0.8* (−1.2 to −0.4) | Gallbladder and biliary tract | 0.7* (0.7 to 1.2) | 0.7* (0.7 to 1.2) | Testis | −0.3 (−1.2 to 0.6) | −0.3 (−1.2 to 0.6) | −0.3 (−1.2 to 0.6) | Kidney | −1.7 (−3.5 to 0.1) | 2.1* (1.4 to 2.8) | 2.6* (1.8 to 3.3) |
| Testis | 2.0* (1.1 to 2.8) | 0.3 (−0.3 to −0.9) | Non-Hodgkin lymphoma | 4.2* (3.3 to 5.0) | 2.6* (1.3 to 3.8) | Brain | −2.6* (−4.1 to −1.0) | 0.9* (0.3 to 1.6) | 1.4* (0.6 to 2.1) | Non-Hodgkin lymphoma | 0.3 (−3.2 to 3.9) | 1.0* (0.6 to 1.3) | 1.0* (0.6 to 1.3) |
| Gallbladder and biliary tract | 2.4* (1.9 to 3.0) | 2.4* (1.9 to 3.0) | Liver | 2.1* (1.6 to 2.6) | 2.1* (1.6 to 2.6) | Non-Hodgkin lymphoma | −0.2 (−1.1 to 0.7) | 0.7* (0.1 to 1.3) | 1.8* (0.9 to 2.6) | Multiple myeloma | −0.4 (−5.0 to 4.3) | 1.9* (1.3 to 2.6) | 1.9* (1.3 to 2.6) |
| Soft tissue | 5.9* (3.3 to 8.6) | 2.3* (1.2 to 3.5) | Soft tissue | 5.6* (2.7 to 8.7) | 1.7* (0.6 to 2.8) | Hodgkin lymphoma | −8.7* (−11.6 to −5.7) | −1.2 (−3.0 to 0.7) | 2.8* (0.2 to 5.5) | Melanoma of skin | 1.1* (0.5 to 1.6) | 1.1* (0.5 to 1.6) | 1.1* (0.5 to 1.6) |
| Bones and joints | 0.1 (−0.6 to 0.7) | 0.1 (−0.6 to 0.7) | Thyroid | 4.2* (1.2 to 7.3) | 2.5* (1.8 to 3.3) | Multiple myeloma | −0.8 (−10.7 to 10.2) | 1.5* (0.6 to 2.5) | 1.5* (0.6 to 2.5) | Bones and joints | −6.7* (−7.8 to −5.6) | −6.7* (−7.8 to −5.6) | −6.7* (−7.8 to −5.6) |
| Thyroid | 3.2* (2.7 to 3.7) | 3.2* (2.7 to 3.7) | Bones and joints | 0.1 (−0.5 to 0.7) | 0.1 (−0.5 to 0.7) | Melanoma of skin | 1.9* (1.5 to 2.2) | 1.9* (1.5 to 2.2) | 1.9* (1.5 to 2.2) | ||||
Notes: Positive APC values represent increase while negative values decrease in yearly incidence rates.
*
APC is significantly different from zero at p < 0.05.
Abbreviations: APC, annual percent change; CI, confidence interval